Form 4: Avid Bioservices Director Jeanne Thoma Reports Stock Transactions

Director Jeanne Thoma of Avid Bioservices, Inc. reports the vesting and acquisition of restricted stock units on December 14, 2024.

Summary

• Jeanne Thoma, a director at Avid Bioservices, Inc., reported transactions involving restricted stock units (RSUs).
• On December 14, 2024, 26,756 RSUs granted in 2023 vested, converting into common stock.
• Also on December 14, 2024, Thoma received an annual equity award of 8,147 RSUs.
• The vested RSUs were converted to common stock, while the newly granted RSUs will vest on December 14, 2025, subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects standard director compensation practices and does not indicate any unusual or concerning activity. The vesting of RSUs and the grant of new RSUs are positive indicators of alignment between the director and the company's long-term goals.

Positives

• The vesting of RSUs indicates that performance conditions were met for the 2023 grant.
• The annual equity award of 8,147 RSUs shows continued alignment of director interests with the company's long-term success.

Risks

• The vesting of RSUs is contingent on continued service, which introduces a risk of forfeiture if the director leaves the company before the vesting date.

Future Outlook

The newly granted RSUs will vest on December 14, 2025, subject to the director's continued service.

Industry Context

This is a standard SEC Form 4 filing related to director compensation, which is common practice in publicly traded companies. The use of RSUs is a typical method for aligning director interests with shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of director compensation is a common practice among publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• Companies like Catalent and Lonza also use equity-based compensation for their directors, often with similar vesting schedules.
• The specific number of RSUs granted and their vesting terms are typically determined by the company's compensation policies and the director's role and responsibilities.

Stakeholder Impact

• The vesting of RSUs and the grant of new RSUs align the director's interests with those of shareholders.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• The director will continue to serve on the board, and the newly granted RSUs will vest on December 14, 2025, if service continues.

Key Dates

Keywords

Avid Bioservices, Director, Stock Transactions, Restricted Stock Units, RSU, Equity Award, Vesting, Common Stock, SEC Form 4